N-benzyl-N-ethylcarbamoyl chloride | 64032-60-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-N-ethylcarbamoyl chloride
• 英文别名: benzyl(ethyl)carbamoyl chloride；N-ethyl-N-benzylcarbamoyl chloride；benzyl-ethyl-carbamyl chloride；N-Ethyl-N-benzylcarbamoylchlorid；Carbamic chloride, N-ethyl-N-(phenylmethyl)-
• CAS: 64032-60-6
• 化学式: C₁₀H₁₂ClNO
• 分子量: 197.664
• InChiKey: HFWOEYXMOCJUBF-UHFFFAOYSA-N

物化性质

• 沸点：
  316.0±21.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-benzyl-N-ethylcarbamoyl chloride 在 4-二甲氨基吡啶 、 苯甲醚 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成 4-<(4-carboxyphenyl)oxy>-3,3-diethyl-1-(N-ethyl-N-benzylcarbamoyl)-2-azetidinone
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003
• 作为产物：
  描述：

  光气 、 N-乙基苄胺 以 苯 为溶剂， 生成 N-benzyl-N-ethylcarbamoyl chloride
  参考文献：
  名称：

  N-烷基-N-苄基-和N-烷基-N-(α-氯苄基)氨基甲酰氯的质子核磁共振谱和构象

  摘要：

  关于十二个 N-烷基-N-苄基氨基甲酰氯（C6H5CHX-NR-COCl，1：X=H，2：X=Cl；R=CH3，C2H5，n-和 i-C3H7）的酰胺 C-N 键的旋转异构化、n-和t-C4H9)通过质子核磁共振光谱研究。异构化的 ΔG\eweq 值对于化合物 1 为 15.8-17.3 kcal/mol，对于化合物 2 为 13.3-15.9 kcal/mol。观察到另一种缓慢旋转是关于 1（R=t- C4H9) 和 2(R=CH3) 在低温下的 α-氯苄基-氮键。化合物 2 的手性中心对 2(R=n-C3H7) 和 2(R=n-C4H9) 的 2-亚甲基的孪生质子和 2(R= i-C3H7)，反映了这些化合物的一些构象偏好。

  DOI：

  10.1246/bcsj.50.1872

文献信息

• N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：HUTCHINSON John Howard

  公开号：US20090197959A1

  公开（公告）日：2009-08-06

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD 2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本发明描述了PGD2受体的拮抗剂化合物。同时，还描述了包含本发明所述化合物的药物组合物，以及使用这些PGD2受体拮抗剂的方法，单独使用或与其他化合物联合使用，用于治疗呼吸系统、心血管系统以及其它依赖或由PGD2介导的条件或疾病。
• Novel Carbamates as Potent Histamine H₃ Receptor Antagonists with High <i>in Vitro</i> and Oral <i>in Vivo</i> Activity^,
  作者：Holger Stark、Katja Purand、Xavier Ligneau、Agnès Rouleau、Jean-Michel Arrang、Monique Garbarg、Jean-Charles Schwartz、Walter Schunack

  DOI：10.1021/jm9507688

  日期：1996.1.1

  their H3 receptor antagonist activity. Different chain lengths and various substituents possessing different electronic and steric parameters were introduced and structure-activity relationships established. In different functional tests, the new antagonists showed high H3 receptor antagonist potencies in vitro (-log Ki values of 6.4-8.4) at synaptosomes of rat cerebral cortex and low activities at histamine

  已知的组胺H3受体拮抗剂burimamide，thioperamide，clobenpropit和相关的homogenamine thioamide衍生物被用作模板，以寻找新的线索。通过用相应的异氰酸酯或氨基甲酰氯处理醇，以高收率制备了结构上被描述为3-（1H-咪唑-4-基）丙醇的氨基甲酸酯衍生物的新型组胺H3受体拮抗剂，并研究了它们的H3受体拮抗剂活性。介绍了不同的链长和具有不同的电子和空间参数的各种取代基，并建立了结构-活性关系。在不同的功能测试中，新的拮抗剂在体外显示出较高的H3受体拮抗剂效价（对数Ki值为6.4-8。4）在大鼠大脑皮层的突触小体，组胺H1和H2受体亚型的活性低。口服给药后，还筛选了它们在小鼠中的中心体内活性。最有前途的化合物（2、16、19）的ED（50）值约为1-2 mg / kg，因此是治疗H3受体依赖性疾病的潜在药物。一些新颖的氨基甲酸酯衍生物是具有高体外和体内活性的H
• [EN] NOVEL TETRAZOLONE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS TÉTRAZOLONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014198592A1

  公开（公告）日：2014-12-18

  The invention relates to a compound of formula (I), wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  该发明涉及一种化合物，其化学式为（I），其中R1和R2如描述和索赔中所定义。化合物的化学式（I）可用作药物。
• Organic Compounds
  申请人：Ehrhardt Claus

  公开号：US20080194549A1

  公开（公告）日：2008-08-14

  The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.

  本发明涉及使用(3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-)取代吡咯烷化合物制备治疗依赖于肾素活性的疾病的药物制剂；使用该类化合物治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病；该取代吡咯烷化合物亚类的新化合物；包括所述取代吡咯烷化合物的药物制剂和/或包括给予所述取代吡咯烷化合物的治疗方法，特别是制备该新取代吡咯烷化合物的方法，以及其合成的新中间体、起始材料和/或部分步骤。
• N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
  申请人：Panmira Pharmaceuticals, LLC

  公开号：US08067445B2

  公开（公告）日：2011-11-29

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包含这些PGD2受体拮抗剂化合物的药物组合物和药物。本文还描述了使用这些PGD2受体拮抗剂，单独或与其他化合物结合，治疗呼吸系统、心血管系统和其他依赖或介导于PGD2的疾病或病症的方法。